Bicycle Therapeutics plc (BCYC) fundamentals score
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, which it refers to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.7 out of 10, Weak long-term fundamentals
- Growth: 5.0/10
- Profitability: 3.3/10
- Financial health: 4.6/10
- Earnings quality: 4.4/10
- Valuation: 7.0/10
Scores are calculated from Bicycle Therapeutics plc’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10